✦ LIBER ✦

Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease

✍ Scribed by William J. Sandborn; Subrata Ghosh; Julian Panes; Ivana Vranic; J. Spanton; Wojciech Niezychowski

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 Study of CP-690,550, an Oral Jan

✍ William J. Sandborn; Subrata Ghosh; Julian Panes; Ivana Vranic; Chinyu Su; J. Sp 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Su2090 A Population Pharmacokinetic Mode

✍ Gao, Xiang; Krishnaswami, Sriram; Mukherjee, Arnab 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 150 KB

An evaluation of the effect of tasocitin

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Tofacitinib (CP-690,550), an oral Janus

✍ Mamolo, C.; Harness, J.; Tan, H.; Menter, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Tasocitinib (CP-690,550), an oral Janus

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

The itch severity item: Mediation modeli

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB